This site is intended for healthcare professionals
FDA Hero Banner - Multi-coloured pills and tablets
FDA Drug information

Dihydroergotamine Mesylate

Read time: 1 mins
Marketing start date: 28 Apr 2024
...
 

Summary of product characteristics


Adverse Reactions

ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Effective Time

20230317

Version

1

Spl Product Data Elements

Dihydroergotamine Mesylate Dihydroergotamine Mesylate DIHYDROERGOTAMINE MESYLATE DIHYDROERGOTAMINE GLYCERIN ALCOHOL METHANESULFONIC ACID SODIUM HYDROXIDE WATER

Application Number

ANDA040453

Brand Name

Dihydroergotamine Mesylate

Generic Name

Dihydroergotamine Mesylate

Product Ndc

62778-336

Product Type

HUMAN PRESCRIPTION DRUG

Route

INTRAMUSCULAR,INTRAVENOUS,SUBCUTANEOUS

Package Label Principal Display Panel

PRINCIPAL DISPLAY PANEL NDC 0143- 9151 -01 Rx only Dihydroergotamine Mesylate Injection, USP 1 mg/mL For IV, IM or SC Use ONLY 1 mL Single-Dose Vial NDC 0143- 9151 -10 Rx only Dihydroergotamine Mesylate Injection, USP 1 mg/mL For Intramuscular, Intravenous or Subcutaneous Use ONLY 10 x 1 mL Single-Dose Vials vial label Carton

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.